Nelson Vallejo, MD
Internal Medicine · Las Piedras, PRNPI 1306812243
Payments from drug & device makers
Across 688 payments — averaging $903.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$472K
- Johnson & Johnson$49K
- Gilead$48K
- Theratechnologies Inc.$20K
- Merck$20K
- Janssen Products, LP$7K
- plus $4K from 10 others
What the payments were for
- Consulting fees$32,3405%
- Speaking & faculty fees$556,78090%
- Travel & lodging$17,5393%
- Food & beverage$14,3052%
- Education$3590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 424 | $472,400 |
| Johnson & Johnson | 80 | $49,476 |
| Gilead | 73 | $48,264 |
| Theratechnologies Inc. | 20 | $20,104 |
| Merck | 35 | $19,983 |
| Janssen Products, LP | 18 | $7,056 |
| Medicure Pharma Inc. | 2 | $3,000 |
| Actelion Pharmaceuticals US, Inc. | 4 | $295 |
| Boehringer Ingelheim | 5 | $235 |
| Sanofi-aventis U.S. LLC | 10 | $220 |
| AstraZeneca | 11 | $167 |
| Novo Nordisk | 1 | $32 |
| PBG Puerto Rico LLC | 1 | $30 |
| GSK | 2 | $30 |
| Johnson And Johnson International | 1 | $17 |
| AbbVie | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$621,323 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DovatoDolutegravir Sodium/Lamivudine | 292 | $1,059,601 |
| JulucaDolutegravir/Rilpivirine | 109 | $491,599 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 67 | $392,994 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 55 | $235,519 |
| Egrifta SvTesamorelin Acetate | 25 | $184,257 |
| FarxigaDapagliflozin Propanediol | 100 | $147,466 |
| TivicayDolutegravir Sodium | 33 | $96,207 |
| JanumetSitagliptin Phos/Metformin Hcl | 69 | $81,532 |
| JardianceEmpagliflozin | 51 | $71,230 |
| PrezcobixDarunavir/Cobicistat | 16 | $58,148 |
| XareltoRivaroxaban | 16 | $28,268 |
| JanuviaSitagliptin Phosphate | 14 | $20,954 |
| EliquisApixaban | 24 | $19,542 |
| SynthroidLevothyroxine Sodium | 170 | $18,888 |
| Maraviroc | 14 | $15,784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Juluca, Tivicay | $472,400 | $1,647,407434 claims |
| Janssen Products, LPSymtuza | $7,056 | $392,99467 claims |
| GileadBiktarvy | $48,264 | $235,51955 claims |
| Theratechnologies Inc.Egrifta Sv | $20,104 | $184,25725 claims |
| AstraZenecaFarxiga | $167 | $147,466100 claims |
| MerckJanumet, Januvia | $19,983 | $102,48683 claims |
| Johnson & JohnsonPrezcobix, Xarelto, Invokana | $49,476 | $100,52847 claims |
| Boehringer IngelheimJardiance | $235 | $71,23051 claims |
| AbbVieSynthroid | $15 | $18,888170 claims |
| Novo NordiskOzempic | $32 | $10,92311 claims |
| Sanofi-aventis U.S. LLCLantus | $220 | $8,11452 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Other internal medicine in Las Piedras
- Elizabeth BarrancoPonce$8M
- Grisell Ortiz LasantaSan Juan$5.9M
- Ruben Santiago-LugoGuaynabo$1.3M
- Ricardo FernandezSan Juan$480K
- Ronald Collazo PaganManati$206K
- Evelyn Matta FontanetRio Grande$200K
- Angel VinuelaDorado$182K
- Lumen Vera ColonAibonito$179K
- Pedro del Valle de TomasSan Juan$114K
- Julio JimenezSan Lorenzo$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.